{"meta":{"query_hash":"31c98ffb0e4d","filters":{"venue":"Liver Cancer"},"cohort_total":19,"direct_labels_cover":0,"predictions_cover":19,"exported":19,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/31c98ffb0e4d","api":"https://metacan.xera.ac/api/v1/cohort?venue=Liver+Cancer"},"results":[{"id":"W2106822989","doi":"10.1007/978-1-4020-9804-8_7","title":"Intraoperative Magnetic Resonance Imaging for Radiofrequency Ablation of Hepatic Tumors","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Debulking; Radiofrequency ablation; Magnetic resonance imaging; Radiology; Ablation; Interventional magnetic resonance imaging; Cancer","score_opus":0.036948709249089606,"score_gpt":0.2508398812122156,"score_spread":0.21389117196312601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106822989","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006538263,0.60494494,0.07319394,0.0047322274,0.005491839,0.00014003807,0.00022671881,0.0006881716,0.30404383],"genre_scores_gemma":[0.043273713,0.4770166,0.10898159,0.0047326325,0.00715258,0.00026279205,0.0004595973,0.0004980282,0.35762244],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999504,0.0000104990295,0.0000039716424,0.0000059812483,0.000025577066,0.0000035540002],"domain_scores_gemma":[0.99986494,0.00009560395,0.000008868179,0.0000067084698,0.000016456888,0.000007422314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025910785,0.00062747503,0.00039767157,0.0007324402,0.00011535235,0.000421328,0.00056112086,0.00061468745,0.0068831095],"category_scores_gemma":[0.0003758128,0.00018946415,0.0002482999,0.00040667038,0.00029012878,0.00088318804,0.00031311365,0.0011833429,0.0038939405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050295734,0.00006207,0.00033469824,0.0008329081,0.000017898692,0.0013037215,0.00020043434,0.00078539475,0.01028959,0.013055554,0.0894654,0.8836022],"study_design_scores_gemma":[0.000015626463,0.000106362764,0.0018391865,0.00083694997,0.00003163637,0.024474226,0.00006445208,0.0011399373,0.0047141854,0.012702574,0.95403475,0.000040103256],"about_ca_topic_score_codex":0.00041794957,"about_ca_topic_score_gemma":0.0016449819,"teacher_disagreement_score":0.0068831095,"about_ca_system_score_codex":0.00020032228,"about_ca_system_score_gemma":0.00029403873,"threshold_uncertainty_score":0.023026288},"labels":[],"label_agreement":null},{"id":"W2131550821","doi":"10.1007/978-1-4020-9804-8_5","title":"Selection of Patients for Resection of Hepatic Colorectal Metastases: 18F-Fluorodeoxyglucose/Positron Emission Tomography","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Positron emission tomography; Colorectal cancer; Radiology; Fluorodeoxyglucose; Stage (stratigraphy); Cancer; Internal medicine","score_opus":0.030148028319682434,"score_gpt":0.2518629784872493,"score_spread":0.22171495016756687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131550821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46151042,0.09924823,0.101716325,0.030343957,0.0045179087,0.00077656336,0.0037420073,0.0009435984,0.297201],"genre_scores_gemma":[0.7910021,0.043541793,0.08162378,0.004829286,0.0024083396,0.0003498055,0.0035392668,0.00026303242,0.07244261],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99995565,0.000013843996,0.0000043231967,0.000005090824,0.00001543526,0.0000057336615],"domain_scores_gemma":[0.99993324,0.000030764568,0.000008538369,0.0000033615977,0.000009974409,0.00001400921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020768102,0.00023810158,0.00031615555,0.00031903505,0.00013878917,0.00025419905,0.00014591182,0.00021342166,0.0029492879],"category_scores_gemma":[0.0005265943,0.00008033193,0.00013937747,0.0002553787,0.00010095515,0.00015537463,0.000102329024,0.0002585161,0.0011840763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052363705,0.00011953888,0.11375689,0.00019682954,0.000033863213,0.00521435,0.00024212686,0.001261034,0.012238716,0.0026804926,0.07579494,0.7879376],"study_design_scores_gemma":[0.00019357396,0.0011547998,0.42155278,0.00068925903,0.0001414868,0.08725201,0.0014475916,0.005755785,0.01339392,0.013906148,0.454365,0.00014773742],"about_ca_topic_score_codex":0.00072293665,"about_ca_topic_score_gemma":0.002383957,"teacher_disagreement_score":0.0029492879,"about_ca_system_score_codex":0.00015194216,"about_ca_system_score_gemma":0.00026590153,"threshold_uncertainty_score":0.009866357},"labels":[],"label_agreement":null},{"id":"W2559460526","doi":"10.1159/000449346","title":"Hepatocellular Carcinoma: The Role of Interventional Oncology","year":2016,"lang":"en","type":"review","venue":"Liver Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Liver transplantation; Incidence (geometry); Surgical resection; Internal medicine; Oncology; Transplantation; General surgery","score_opus":0.047641164081696316,"score_gpt":0.3697047981926722,"score_spread":0.3220636341109759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559460526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009031815,0.99780506,0.000116554234,0.0007573852,0.00024638275,0.0000018129684,0.0000057731136,0.0000053944987,0.0009712705],"genre_scores_gemma":[0.0011551365,0.9975304,0.00017095711,0.0003078035,0.00044033982,0.000003276623,0.00001077423,0.0000014404615,0.00037974675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997919,0.00005480152,0.000027934595,0.000033681194,0.00007275686,0.000019003342],"domain_scores_gemma":[0.9995641,0.00022505895,0.000049057708,0.000013223564,0.00011342065,0.000035064677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064595364,0.0005445819,0.0007474155,0.0015246919,0.0002853171,0.0009955217,0.0004779789,0.00100956,0.0026360457],"category_scores_gemma":[0.00088211906,0.00012790729,0.00037490836,0.0012549434,0.0005985116,0.0013177213,0.00055326225,0.0015049673,0.00097352284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035278397,0.000030255926,0.00029097105,0.008285784,0.000049382466,0.00030761343,0.00008391578,0.00023750967,0.00068988965,0.0062694787,0.026719471,0.9570004],"study_design_scores_gemma":[0.000008094335,0.000055386794,0.0007162701,0.003958865,0.000067964356,0.0031067028,0.000098475924,0.00008064635,0.0003152775,0.0032600658,0.9883158,0.000016310916],"about_ca_topic_score_codex":0.0008137651,"about_ca_topic_score_gemma":0.0011522549,"teacher_disagreement_score":0.0026360457,"about_ca_system_score_codex":0.0006090379,"about_ca_system_score_gemma":0.0011992862,"threshold_uncertainty_score":0.008818448},"labels":[],"label_agreement":null},{"id":"W3139664658","doi":"10.36255/exonpublications.livercancer.2021.ch4","title":"Gross Dissection of Liver for Hepatocellular Carcinoma Using AJCC Cancer Staging Manual 8th Edition: Anatomical and Practical Considerations","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta; University of Alberta Hospital","funders":"","keywords":"Dissection (medical); Hepatocellular carcinoma; Medicine; Liver cancer; Cancer; General surgery; Terminology; Resection; Pathology; Radiology; Surgery; Internal medicine","score_opus":0.07437325643932621,"score_gpt":0.348629559974269,"score_spread":0.2742563035349428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139664658","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026569206,0.11224678,0.051894475,0.017936539,0.012775288,0.00078374404,0.0035277887,0.0021501032,0.7960283],"genre_scores_gemma":[0.010298366,0.10488649,0.1408793,0.0092066685,0.0037137053,0.000535441,0.0043525505,0.0011961029,0.7249314],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978083,0.000032597065,0.000020440824,0.000020359132,0.00013510876,0.000010515885],"domain_scores_gemma":[0.99969757,0.000118179305,0.000024223034,0.000015711848,0.000121620404,0.000022659327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048688965,0.00077319477,0.00040504886,0.0014434679,0.0005398711,0.00081716006,0.00061705714,0.00063100737,0.026839942],"category_scores_gemma":[0.00075404486,0.0003109601,0.00033865642,0.0010344628,0.0005045266,0.0010681968,0.0005693126,0.001879054,0.02247539],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012262374,0.000033090793,0.00029788222,0.00042944687,0.0000036981498,0.00025408724,0.000334932,0.0003380363,0.0011071742,0.010797396,0.6793328,0.30705914],"study_design_scores_gemma":[0.0000013711553,0.000014589979,0.00078603416,0.00025902086,0.0000023340647,0.0012932178,0.000057700854,0.00011445261,0.00015990809,0.0036910856,0.993612,0.000008336707],"about_ca_topic_score_codex":0.002358545,"about_ca_topic_score_gemma":0.010562278,"teacher_disagreement_score":0.026839942,"about_ca_system_score_codex":0.00048535608,"about_ca_system_score_gemma":0.0010464585,"threshold_uncertainty_score":0.089788556},"labels":[],"label_agreement":null},{"id":"W3173725877","doi":"10.1159/000513486","title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Bevacizumab; Medicine; Internal medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Gastroenterology; Progression-free survival; Population; Phases of clinical research; Oncology; Clinical endpoint; Randomized controlled trial; Clinical trial; Confidence interval; Cancer; Chemotherapy; Nivolumab; Immunotherapy","score_opus":0.10695670752842361,"score_gpt":0.34804486855848377,"score_spread":0.24108816103006014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173725877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971781,0.00089478475,0.00011869073,0.00021890004,0.000038644746,0.0006839544,0.0003651895,0.000020695934,0.00048107447],"genre_scores_gemma":[0.9958825,0.0006178578,0.00035966022,0.0005725253,0.00008450017,0.0008875394,0.000980798,0.0000071612017,0.000607497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995542,0.00021391951,0.000029426741,0.000077687524,0.00005680755,0.00006791734],"domain_scores_gemma":[0.9992017,0.00011432109,0.00020095457,0.000081571896,0.000074915355,0.0003265665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020663922,0.0010696688,0.0019936354,0.00029789965,0.000316749,0.0005023197,0.00073448394,0.00075755495,0.0020165585],"category_scores_gemma":[0.0010964966,0.0003582928,0.001763876,0.00042743154,0.00068722374,0.00049873977,0.00036893555,0.0013852423,0.000371874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.928539,0.010936605,0.0142802335,0.00069926714,0.0036442836,0.0001268874,0.00024605953,0.0007816195,0.0065586064,0.00010730719,0.001634795,0.032445308],"study_design_scores_gemma":[0.79748935,0.1423397,0.052114766,0.000047367197,0.003189948,0.00013138045,0.00009895048,0.0013193323,0.0012211992,0.00019414513,0.0018025095,0.000051307034],"about_ca_topic_score_codex":0.0024879551,"about_ca_topic_score_gemma":0.006625447,"teacher_disagreement_score":0.0024879551,"about_ca_system_score_codex":0.0011203346,"about_ca_system_score_gemma":0.002396779,"threshold_uncertainty_score":0.010928214},"labels":[],"label_agreement":null},{"id":"W3185994964","doi":"10.1159/000516490","title":"Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eisai","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Liver function; Adverse effect; Oncology; Overall survival; Post-hoc analysis; Gastroenterology","score_opus":0.05933619209472887,"score_gpt":0.2809289060137234,"score_spread":0.22159271391899452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185994964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979905,0.00045733983,0.00010462999,0.00013981343,0.00001079039,0.00007393779,0.0007485377,0.00000890955,0.0004655757],"genre_scores_gemma":[0.99756515,0.00014519414,0.00013870305,0.00012222548,0.000034211982,0.00008293356,0.0017009455,0.0000047893936,0.00020581608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991258,0.00050708966,0.00005686302,0.00010047401,0.00012915398,0.000080745616],"domain_scores_gemma":[0.99806136,0.00027591854,0.0008942071,0.00017644811,0.00021150829,0.0003805374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002918689,0.00050790084,0.0005939928,0.0003213768,0.000264878,0.00066685193,0.00037005273,0.00035611627,0.0011334929],"category_scores_gemma":[0.0022552395,0.00029430207,0.0007501653,0.0005263115,0.00023326813,0.0004912988,0.0004751631,0.00097466307,0.00032725904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060169663,0.0029574088,0.91224766,0.00014493254,0.001889281,0.0001294203,0.000111440306,0.0009950799,0.004288273,0.000086005806,0.0023862303,0.014594631],"study_design_scores_gemma":[0.005299159,0.014318833,0.97641784,0.000015016765,0.0005747324,0.00031895397,0.00006815129,0.0011123801,0.0007622217,0.000070793976,0.0010169296,0.000024834535],"about_ca_topic_score_codex":0.00075422885,"about_ca_topic_score_gemma":0.0013543746,"teacher_disagreement_score":0.002918689,"about_ca_system_score_codex":0.0004935558,"about_ca_system_score_gemma":0.00046981304,"threshold_uncertainty_score":0.015435696},"labels":[],"label_agreement":null},{"id":"W4249856389","doi":"10.36255/exonpublications.livercancer.2021.pr","title":"Preface","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Stollery Children's Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Etiology; Fatty liver; Cancer; Liver cancer; Disease; Pathology; Internal medicine","score_opus":0.09531691578801603,"score_gpt":0.261330717019093,"score_spread":0.16601380123107695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249856389","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001028787,0.01235888,0.003819509,0.014142222,0.06789108,0.0002714368,0.0027974215,0.000956588,0.89673394],"genre_scores_gemma":[0.0022614994,0.004570603,0.001610855,0.0031700793,0.00717049,0.000081626335,0.0018400999,0.0003734415,0.97892135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959034,0.00004963553,0.000021145477,0.00008002054,0.00022192574,0.00003706771],"domain_scores_gemma":[0.9986916,0.00023443312,0.00005049618,0.00009372465,0.00069510675,0.00023464025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004848079,0.0008510367,0.00064961833,0.001441566,0.0016143195,0.0031362502,0.0009911333,0.0010837106,0.38357118],"category_scores_gemma":[0.0027216207,0.0003072939,0.000510085,0.0011094058,0.00050688203,0.0025293506,0.0015280166,0.0026759007,0.27139693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000128719275,0.000017665547,0.00006345665,0.00008873663,0.0000012567605,0.0000617918,0.000092349495,0.00005575613,0.00015730962,0.0051625976,0.95263016,0.041655973],"study_design_scores_gemma":[0.000001307445,0.0000064540627,0.00009519189,0.00006353641,5.8290385e-7,0.00009755967,0.000042208285,0.000020777916,0.00003688701,0.0009788891,0.9986545,0.0000019704287],"about_ca_topic_score_codex":0.0016762329,"about_ca_topic_score_gemma":0.0024849193,"teacher_disagreement_score":0.38357118,"about_ca_system_score_codex":0.0012499201,"about_ca_system_score_gemma":0.001120166,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4303470795","doi":"10.1159/000526899","title":"PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft; Government of Canada; Wilhelm Sander-Stiftung","keywords":"Blockade; CD8; Cytotoxic T cell; Medicine; Cancer research; Priming (agriculture); Tumor-infiltrating lymphocytes; Tumor microenvironment; Immunology; Nivolumab; Immunotherapy; Immune system; Biology; Internal medicine; Receptor","score_opus":0.02389854169721906,"score_gpt":0.3067304720411475,"score_spread":0.28283193034392845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303470795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973617,0.00050050224,0.0010121951,0.000060692102,0.000038822538,0.000039826202,0.00018628758,0.00015497311,0.0006449028],"genre_scores_gemma":[0.99620736,0.0002577219,0.00094937894,0.000040220435,0.000018703437,0.00008883532,0.0005207471,0.000033066262,0.0018841164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998677,0.000016983347,0.000014117338,0.000027980679,0.000026442558,0.000046802368],"domain_scores_gemma":[0.99984896,0.000022642043,0.00003653333,0.000024839877,0.00000627465,0.000060619204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014681408,0.0005488503,0.0004079016,0.00037934474,0.00014944986,0.0001922163,0.00021092288,0.00022227601,0.0016736311],"category_scores_gemma":[0.000100240206,0.00014852162,0.00027373602,0.000153233,0.00028452364,0.00022140352,0.00016767066,0.001117551,0.0003466435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014415138,0.0009317437,0.00027234174,0.00009357455,0.000012031726,0.000079078774,0.000032090757,0.00023455506,0.9933602,0.00008473855,0.00016388722,0.0032942484],"study_design_scores_gemma":[0.00019790651,0.004670238,0.002002072,0.0000060670027,0.000024961186,0.00019085612,0.00001747066,0.0013022519,0.99066824,0.00003962504,0.00087587006,0.000004502439],"about_ca_topic_score_codex":0.00044983183,"about_ca_topic_score_gemma":0.00058228837,"teacher_disagreement_score":0.0016736311,"about_ca_system_score_codex":0.00031457737,"about_ca_system_score_gemma":0.0002653464,"threshold_uncertainty_score":0.0055989027},"labels":[],"label_agreement":null},{"id":"W4303470808","doi":"10.1159/000527403","title":"Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; University of Pittsburgh","keywords":"Regorafenib; Cabozantinib; Discontinuation; Medicine; Hepatocellular carcinoma; Sorafenib; Hazard ratio; Propensity score matching; Adverse effect; Internal medicine; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer","score_opus":0.11114778983446884,"score_gpt":0.32787936060806316,"score_spread":0.21673157077359434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303470808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96485025,0.012727462,0.010235994,0.00057959894,0.00071778736,0.0021548907,0.0036443511,0.000159256,0.004930304],"genre_scores_gemma":[0.99216413,0.0008100961,0.0033320396,0.00028924397,0.00010573705,0.0012257627,0.001141463,0.000017983997,0.0009135263],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98606,0.01071441,0.0007227493,0.0011035707,0.000940073,0.00045912687],"domain_scores_gemma":[0.9928087,0.004377,0.001711882,0.00057575,0.0002442459,0.0002824426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010100079,0.0017329578,0.0029941325,0.00086113776,0.00020569436,0.0012128316,0.0012406649,0.001194742,0.009116656],"category_scores_gemma":[0.018080639,0.00052761845,0.007927529,0.0007074906,0.00068919366,0.0010462382,0.0015637021,0.0019811841,0.00052745704],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8052886,0.0017130603,0.019941278,0.004135375,0.09074791,0.000119875425,0.00023589782,0.011968963,0.0021072295,0.0023097573,0.0014330267,0.05999891],"study_design_scores_gemma":[0.3975382,0.22254032,0.10308888,0.0012212719,0.16721442,0.0008338209,0.000451537,0.07326982,0.0070350235,0.01538302,0.011060667,0.0003630552],"about_ca_topic_score_codex":0.0014463073,"about_ca_topic_score_gemma":0.001133752,"teacher_disagreement_score":0.010100079,"about_ca_system_score_codex":0.000990438,"about_ca_system_score_gemma":0.0008242823,"threshold_uncertainty_score":0.053415},"labels":[],"label_agreement":null},{"id":"W4310183164","doi":"10.1159/000528272","title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Sorafenib; Bevacizumab; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Hazard ratio; Oncology; Liver cancer; Cancer; Phases of clinical research; Gastroenterology; Confidence interval; Chemotherapy; Nivolumab; Immunotherapy","score_opus":0.06051174997819984,"score_gpt":0.2949862541609207,"score_spread":0.2344745041827209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310183164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956157,0.002091164,0.00031139064,0.00021911407,0.00003725541,0.0004248618,0.0005458057,0.000037573685,0.0007171386],"genre_scores_gemma":[0.9966354,0.0005364902,0.0005243206,0.00026873118,0.000062080566,0.00038222296,0.0011579061,0.000010874659,0.00042206267],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988417,0.00077617454,0.0000640716,0.00013508371,0.00009267935,0.00009031606],"domain_scores_gemma":[0.99862564,0.0003214227,0.00044348236,0.00011930867,0.000096178104,0.0003939637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033444515,0.00090108986,0.0015662005,0.0003239188,0.00017937312,0.000994458,0.00074003934,0.0006122946,0.0017323467],"category_scores_gemma":[0.0018955247,0.00044260267,0.0023945703,0.00033551815,0.00047915426,0.0006745421,0.00042566887,0.0016515991,0.00049330184],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9063448,0.012182552,0.017455058,0.0005785669,0.004056783,0.00010762102,0.00015128544,0.0017224833,0.010023351,0.00012511777,0.0015612929,0.04569114],"study_design_scores_gemma":[0.54747814,0.3766801,0.06389563,0.000078729994,0.0031570361,0.00032741437,0.000085679305,0.0031573796,0.0027509478,0.00019906326,0.0021329748,0.000056876506],"about_ca_topic_score_codex":0.0005260748,"about_ca_topic_score_gemma":0.0015720534,"teacher_disagreement_score":0.0033444515,"about_ca_system_score_codex":0.00095367804,"about_ca_system_score_gemma":0.0010647187,"threshold_uncertainty_score":0.01768732},"labels":[],"label_agreement":null},{"id":"W4320717208","doi":"10.1159/000529636","title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Chugai Pharmaceutical; Sirtex Medical; Ipsen; Servier; Ono Pharmaceutical; Eisai; Sanofi; Bayer HealthCare; Incyte; EA Pharma Co., Ltd.; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hepatocellular carcinoma; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Physics","score_opus":0.09416067897063918,"score_gpt":0.32119857496285903,"score_spread":0.22703789599221985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320717208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94654965,0.03140183,0.001467703,0.0018676493,0.00046278868,0.0021922449,0.010217354,0.0001508174,0.005690099],"genre_scores_gemma":[0.9709599,0.006372266,0.0010197355,0.0020434055,0.00044642045,0.0024676553,0.013933448,0.00004629873,0.0027108924],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99875236,0.00069405994,0.000086813154,0.00016165341,0.00013458969,0.00017060168],"domain_scores_gemma":[0.9980258,0.0004587926,0.0006402791,0.00025667605,0.00017695209,0.0004415977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058083865,0.0010365419,0.0019417771,0.0002344222,0.00046362754,0.0015656145,0.00054781855,0.0012281138,0.005205329],"category_scores_gemma":[0.0029238795,0.00033052813,0.0028859028,0.00047363256,0.0004345537,0.0010199662,0.0005404472,0.0028161432,0.0010242215],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9174783,0.002680046,0.004928156,0.0017384205,0.0062883105,0.00020059985,0.000113781105,0.0013039254,0.004563342,0.00022307065,0.0074937935,0.05298817],"study_design_scores_gemma":[0.8402644,0.085571766,0.047584694,0.0005056655,0.009712051,0.0006379948,0.00008094208,0.0011073694,0.0021636935,0.0008046257,0.011481529,0.00008528081],"about_ca_topic_score_codex":0.0006758229,"about_ca_topic_score_gemma":0.0014054171,"teacher_disagreement_score":0.0058083865,"about_ca_system_score_codex":0.00083472393,"about_ca_system_score_gemma":0.0008950172,"threshold_uncertainty_score":0.030718029},"labels":[],"label_agreement":null},{"id":"W4323307162","doi":"10.1159/000529996","title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Bevacizumab; Medicine; Atezolizumab; Sorafenib; Internal medicine; Hepatocellular carcinoma; Liver function; Gastroenterology; Population; Post-hoc analysis; Oncology; Tolerability; Clinical endpoint; Surgery; Randomized controlled trial; Adverse effect; Cancer; Chemotherapy; Nivolumab","score_opus":0.09168397289620757,"score_gpt":0.3275482401496349,"score_spread":0.23586426725342735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323307162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950321,0.0018065945,0.0006310269,0.00028263652,0.00012693125,0.0004694325,0.00091482233,0.000044574652,0.0006918991],"genre_scores_gemma":[0.99640214,0.00034386571,0.00051009917,0.00021776705,0.00013962155,0.0004177419,0.0011489651,0.000020180007,0.0007997817],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965088,0.0025808979,0.00015626453,0.00035327714,0.00017791033,0.00022282246],"domain_scores_gemma":[0.9962101,0.0014285932,0.0009451533,0.0005262081,0.00023493162,0.00065496645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006293906,0.0016993452,0.0031571458,0.0003266509,0.00021842858,0.0012682497,0.0009383985,0.0007783303,0.00262628],"category_scores_gemma":[0.0049174726,0.0005724066,0.0074066063,0.00040455844,0.0005677774,0.00079599005,0.00057983387,0.0023848189,0.0004336154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96460843,0.0021398698,0.009065394,0.00023651379,0.010818504,0.000045430184,0.00005061737,0.0013422986,0.0020185716,0.000057141606,0.00071804936,0.008899168],"study_design_scores_gemma":[0.54621667,0.30514172,0.11258079,0.00006965526,0.021555109,0.00020460738,0.00011179006,0.007657215,0.0035510045,0.0005060774,0.002310654,0.000094684816],"about_ca_topic_score_codex":0.0007036434,"about_ca_topic_score_gemma":0.0017171344,"teacher_disagreement_score":0.006293906,"about_ca_system_score_codex":0.0010380222,"about_ca_system_score_gemma":0.0012413729,"threshold_uncertainty_score":0.033285737},"labels":[],"label_agreement":null},{"id":"W4388621275","doi":"10.1159/000534303","title":"Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Oncology; Bevacizumab; Atezolizumab; Nivolumab; Adverse effect; Immunotherapy; Gastroenterology; Cancer; Chemotherapy","score_opus":0.05778974049913274,"score_gpt":0.2666817629775639,"score_spread":0.20889202247843117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388621275","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009917717,0.99639964,0.00020026305,0.0015590317,0.00024461068,0.000011984345,0.00003405652,0.0000055506257,0.00055308454],"genre_scores_gemma":[0.011953799,0.9844245,0.0006579733,0.0018321469,0.00066087715,0.000031627176,0.000088290784,0.0000044577546,0.0003462468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994937,0.00019570645,0.00012009854,0.00006381172,0.00010246801,0.000024225674],"domain_scores_gemma":[0.9989586,0.0006121729,0.00026423947,0.000017214086,0.000120780525,0.000026973794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013770498,0.00027832403,0.0013188337,0.0006521085,0.00016121374,0.00073246984,0.00048636828,0.00074723753,0.0027658828],"category_scores_gemma":[0.00238083,0.00010498635,0.0010648677,0.0005628198,0.00034430609,0.0011580858,0.000251852,0.00089982664,0.00045522887],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007001609,0.00010584014,0.0018816201,0.086572476,0.00078953005,0.00056921894,0.0001695374,0.0004837383,0.0013976796,0.0022824677,0.020644225,0.8844035],"study_design_scores_gemma":[0.0010521959,0.0019463883,0.015387521,0.1359884,0.0072192345,0.010625434,0.0009015604,0.0012905269,0.0033415528,0.008988222,0.81310403,0.00015494529],"about_ca_topic_score_codex":0.00049496215,"about_ca_topic_score_gemma":0.0020702956,"teacher_disagreement_score":0.0027658828,"about_ca_system_score_codex":0.00040198598,"about_ca_system_score_gemma":0.0011464783,"threshold_uncertainty_score":0.009252846},"labels":[],"label_agreement":null},{"id":"W4392015401","doi":"10.1159/000537966","title":"Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; BeiGene","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Carcinoma","score_opus":0.16634803674419976,"score_gpt":0.36027343846891813,"score_spread":0.19392540172471837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392015401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853586,0.006333047,0.0004575905,0.0012816694,0.000334792,0.0015004653,0.0023749606,0.000082171326,0.002276765],"genre_scores_gemma":[0.98979515,0.0022672454,0.00088146294,0.00088186655,0.0002781792,0.0014741159,0.0023961219,0.000021753072,0.0020039468],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99870634,0.0009421814,0.000058510017,0.0001024541,0.00009520982,0.00009532702],"domain_scores_gemma":[0.99847585,0.00033208236,0.0004887567,0.00013361845,0.0001283535,0.00044136308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031302257,0.001043735,0.0022497152,0.00026969274,0.00028680102,0.0007699461,0.00070856215,0.00093422487,0.005174889],"category_scores_gemma":[0.002041827,0.0004230346,0.0034470458,0.0003321711,0.00046128323,0.0006070304,0.0004254437,0.0025166364,0.0007300454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9278312,0.009563359,0.0052068844,0.0015236109,0.005453332,0.00008125103,0.00007194188,0.00094260304,0.006950764,0.00016612683,0.0034105468,0.038798448],"study_design_scores_gemma":[0.7799028,0.17854501,0.0317938,0.0001829716,0.004106008,0.00017238563,0.000054869397,0.0015141275,0.0010369434,0.0002302809,0.002405652,0.000055246343],"about_ca_topic_score_codex":0.0010345737,"about_ca_topic_score_gemma":0.004464413,"teacher_disagreement_score":0.005174889,"about_ca_system_score_codex":0.0010391012,"about_ca_system_score_gemma":0.0017916553,"threshold_uncertainty_score":0.017311692},"labels":[],"label_agreement":null},{"id":"W4392151488","doi":"10.1159/000537947","title":"Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Eisai; Plexxikon; Seagen; Pfizer; NuCana; Incyte; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; EA Pharma Co., Ltd.; Merck KGaA; Baxalta; Sirtex Medical; Cancer Research UK; Boston Scientific Corporation; Halozyme; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Radiology; Clinical trial; Phases of clinical research","score_opus":0.043133913455944174,"score_gpt":0.28076085218210206,"score_spread":0.2376269387261579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392151488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242663,0.0042240275,0.00048939895,0.00045293372,0.00005685427,0.00070554944,0.00068334944,0.000044709985,0.0009164712],"genre_scores_gemma":[0.99609345,0.0007705831,0.0005517292,0.00036160965,0.00012001482,0.00075390865,0.0009982339,0.0000072822063,0.00034314767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746907,0.0018255409,0.000158681,0.00026253978,0.00017190527,0.00011233233],"domain_scores_gemma":[0.99779415,0.00068656454,0.0009740301,0.0001744612,0.000104682455,0.00026608675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005168334,0.00064617436,0.0016163767,0.0002907482,0.00019191086,0.0007962127,0.000448409,0.0005428567,0.0018784988],"category_scores_gemma":[0.003484441,0.00028368612,0.0016657589,0.0003143798,0.00052857306,0.00053427584,0.00034879489,0.0011233194,0.00028604025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9057417,0.002418202,0.037350137,0.0007319402,0.004919137,0.0000621913,0.00009991426,0.0011290791,0.004089628,0.00015798146,0.0012049116,0.042095285],"study_design_scores_gemma":[0.6918704,0.14598161,0.1434538,0.00015166902,0.006765815,0.00046453957,0.00010220889,0.0036497426,0.0035504962,0.0006038673,0.003337473,0.00006837993],"about_ca_topic_score_codex":0.00022368024,"about_ca_topic_score_gemma":0.0008000455,"teacher_disagreement_score":0.005168334,"about_ca_system_score_codex":0.0005810795,"about_ca_system_score_gemma":0.00079653366,"threshold_uncertainty_score":0.02733308},"labels":[],"label_agreement":null},{"id":"W4401410496","doi":"10.1159/000540290","title":"Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"National Cancer Institute; University of California, San Francisco; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Memorial Sloan-Kettering Cancer Center","keywords":"Neratinib; Medicine; Sunitinib; Everolimus; Axitinib; Tyrosine-kinase inhibitor; Nivolumab; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Cancer; Immunotherapy; Clinical trial; Breast cancer","score_opus":0.007036782436839323,"score_gpt":0.2275670107357827,"score_spread":0.22053022829894336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401410496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933675,0.0039890213,0.00013172862,0.00030894513,0.0000563776,0.00014834409,0.00022609484,0.000033527984,0.0017384347],"genre_scores_gemma":[0.9976828,0.0009965658,0.0002044248,0.00024114868,0.000043252814,0.00007646945,0.00038660326,0.000005446645,0.00036327264],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978215,0.000068568224,0.000029629864,0.00004147941,0.00003199093,0.000046177254],"domain_scores_gemma":[0.9997303,0.000061013216,0.000062391526,0.000018855482,0.000020450183,0.00010682582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081988715,0.0005534685,0.0014680072,0.00027618738,0.00026881273,0.00056863716,0.0004774575,0.00047645936,0.0010563552],"category_scores_gemma":[0.00073046715,0.00025706476,0.0008232017,0.0004051883,0.00028653975,0.00063612603,0.00021331098,0.00084141036,0.00023418381],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41867465,0.012297846,0.0921144,0.0016878016,0.0030991896,0.003047343,0.0005330373,0.00922303,0.105027266,0.0004516794,0.007970397,0.34587333],"study_design_scores_gemma":[0.18994847,0.43524322,0.2917655,0.00029418318,0.004980878,0.0068109916,0.00062437484,0.012081721,0.036806628,0.0005476847,0.02066749,0.00022880244],"about_ca_topic_score_codex":0.0011205054,"about_ca_topic_score_gemma":0.005187131,"teacher_disagreement_score":0.0014680072,"about_ca_system_score_codex":0.0010725622,"about_ca_system_score_gemma":0.0008777764,"threshold_uncertainty_score":0.0077819824},"labels":[],"label_agreement":null},{"id":"W4404467870","doi":"10.1159/000542146","title":"Acknowledgement to Reviewers","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Acknowledgement; Medicine; Computer science; Computer security","score_opus":0.09618991736786028,"score_gpt":0.32425520200210406,"score_spread":0.22806528463424378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404467870","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030425284,0.01219767,0.0028650642,0.22798607,0.7093457,0.0005496513,0.0016571207,0.0013394654,0.043754905],"genre_scores_gemma":[0.010240925,0.018177718,0.006931029,0.20392054,0.32651845,0.002214993,0.003648573,0.003519402,0.42482835],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96333593,0.011149944,0.004574756,0.0049039777,0.013749991,0.0022854689],"domain_scores_gemma":[0.719859,0.0280475,0.010788851,0.012423506,0.20775348,0.021127595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024531461,0.002549548,0.0023998693,0.0070144525,0.004309461,0.017764682,0.0053149927,0.0073864902,0.23633471],"category_scores_gemma":[0.23705691,0.0009840984,0.0016902592,0.0038385503,0.002552795,0.010594283,0.008561293,0.009297763,0.15850703],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001915812,0.0000047445865,0.0000515579,0.00016430508,0.0000046560317,0.000054150503,0.00013070866,0.000012685649,0.000036145324,0.00092560274,0.98833895,0.010257358],"study_design_scores_gemma":[0.0000098544415,0.0000068173463,0.00008147721,0.00031547435,0.000005906773,0.00013780752,0.00025023398,0.000023410112,0.000036989717,0.00080043264,0.99831885,0.0000126597515],"about_ca_topic_score_codex":0.0026619139,"about_ca_topic_score_gemma":0.0034859297,"teacher_disagreement_score":0.7636653,"about_ca_system_score_codex":0.007551532,"about_ca_system_score_gemma":0.017733017,"threshold_uncertainty_score":0.79061836},"labels":[],"label_agreement":null},{"id":"W4414450104","doi":"10.1159/000548606","title":"Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Overall survival; Clinical endpoint; Progression-free survival; Endpoint Determination; Survival analysis","score_opus":0.1833565736483253,"score_gpt":0.33732170470501216,"score_spread":0.15396513105668685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414450104","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034660492,0.9543215,0.0058375676,0.00081850647,0.0006403061,0.000713571,0.0017721654,0.00015856564,0.0010773408],"genre_scores_gemma":[0.7874979,0.19523132,0.007515875,0.0020810848,0.00082977,0.0027765122,0.0027635442,0.000161493,0.0011424882],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.978208,0.015336528,0.0029468033,0.0018172277,0.0012274613,0.00046398447],"domain_scores_gemma":[0.9737593,0.020222424,0.0031752016,0.0013497471,0.0011207476,0.00037264617],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.027054809,0.0032096547,0.01712846,0.0038678935,0.0005018062,0.0039013436,0.0021739944,0.002456012,0.0035697625],"category_scores_gemma":[0.037625,0.0012359563,0.07350503,0.0043711597,0.0007260788,0.0020299251,0.001716573,0.0032287962,0.00042433006],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005989912,0.000025750243,0.0030667079,0.034482975,0.95115554,0.0000601407,0.00002230241,0.0010592019,0.00017569948,0.00009885971,0.00029069095,0.0035722181],"study_design_scores_gemma":[0.0011921949,0.00025229124,0.0017473956,0.0016582361,0.99370956,0.000036666122,0.00001162761,0.00056918355,0.00007587796,0.00024868583,0.0004843851,0.0000138535415],"about_ca_topic_score_codex":0.002863837,"about_ca_topic_score_gemma":0.0042993757,"teacher_disagreement_score":0.99679035,"about_ca_system_score_codex":0.002025928,"about_ca_system_score_gemma":0.0017731738,"threshold_uncertainty_score":0.14308119},"labels":[],"label_agreement":null},{"id":"W4417466987","doi":"10.1159/000549955","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Ramucirumab; Chemoradiotherapy; Carcinoma","score_opus":0.09119294205123218,"score_gpt":0.3126555805677392,"score_spread":0.221462638516507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417466987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96069586,0.00689229,0.0016555476,0.0015681447,0.00021902009,0.0042190226,0.016381796,0.00036767113,0.008000668],"genre_scores_gemma":[0.97483295,0.0014115742,0.002644035,0.0016648024,0.00022062527,0.0037461093,0.012781282,0.00006195953,0.0026365293],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99815756,0.0011252143,0.00009232961,0.00020449261,0.000267985,0.00015248194],"domain_scores_gemma":[0.9954918,0.001070414,0.0013965247,0.00044760288,0.0005778007,0.0010158548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005940027,0.0008711208,0.0013464533,0.00024897387,0.0004713473,0.0010148301,0.0007901682,0.0009176544,0.005334135],"category_scores_gemma":[0.004673198,0.0005079594,0.0017544968,0.00028277666,0.00046793048,0.00076293596,0.0005246711,0.002327075,0.0012528899],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.846194,0.0102306595,0.033491213,0.0016014697,0.0051376093,0.00020778456,0.00026702462,0.0011042439,0.016631046,0.00039920685,0.016334157,0.06840156],"study_design_scores_gemma":[0.6242553,0.22111808,0.1234829,0.0002315886,0.005422343,0.000753388,0.00012518541,0.0013797061,0.0059162276,0.0006762724,0.016536187,0.000102917766],"about_ca_topic_score_codex":0.00062849256,"about_ca_topic_score_gemma":0.002552075,"teacher_disagreement_score":0.005940027,"about_ca_system_score_codex":0.0006858178,"about_ca_system_score_gemma":0.0015920595,"threshold_uncertainty_score":0.03141421},"labels":[],"label_agreement":null}]}